PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer.

ABSTRACT:

Background

Recent breakthroughs in therapies with immune checkpoint inhibitors (ICIs) have revolutionized the treatment of lung cancer. However, only 15-25% of patients respond to the ICIs therapy, and methods to identify those responsive patients are currently a hot research topic. PD-L1 expression measured on tumor tissues using immunohistochemistry (IHC) was approved as one of the companion diagnostic methods, but it is invasive and cannot be used to monitor dynamic changes in PD-L1 expression during treatments.

Methods

In this study, we developed an Epcam-PD-L1 extracellular vesicle (EV) detection prototype using the Simoa platform. This assay detected PD-L1 expression levels on tumor-derived exosomes from the lung cancer cell lines A549 and SK-MES1. In addition, 35 plas

SUBMITTER: Wu F 

PROVIDER: S-EPMC8264343 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature